UBS analyst Eliana Merle maintains $Apellis Pharmaceuticals (APLS.US)$ with a buy rating, and adjusts the target price from $83 to $45.
According to TipRanks data, the analyst has a success rate of 39.4% and a total average return of -5.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Apellis Pharmaceuticals (APLS.US)$'s main analysts recently are as follows:
Post the Q3 report, there's recognition of a clear opportunity to build a 'post-GA' thesis around the company's prospects. This sentiment is bolstered by strong conviction in the performance and data related to C3G and IC-MPGN, which are viewed as robust and superior to oral competitors in a wider context.
Following Apellis's report of third-quarter Syfovre revenues that fell short of expectations, the underlying sentiment is that the company's current valuation may not fully reflect the prospective size of the market opportunity. While seeking further details on the geographic atrophy (GA) market, there's an anticipation that the potential introduction in C3G/IC-MPGN could balance the more gradual progress in GA.
The firm noted that Apellis disclosed results for the third quarter of 2024, which presented a decline in Syfovre revenue. This was attributed to moderate growth in vial numbers contrasted with a reduced net price and heightened competition.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞士銀行分析師Eliana Merle維持$Apellis Pharmaceuticals (APLS.US)$買入評級，並將目標價從83美元下調至45美元。
根據TipRanks數據顯示，該分析師近一年總勝率為39.4%，總平均回報率為-5.4%。
此外，綜合報道，$Apellis Pharmaceuticals (APLS.US)$近期主要分析師觀點如下：
在第三季度報告發布後，人們認識到了圍繞公司的前景建立 「後GA」 論點的明顯機會。對與C3G和IC-MPGN相關的表現和數據的堅定信念支撐了這種情緒，在更廣泛的背景下，C3G和IC-MPGN被視爲強勁且優於口頭競爭對手。
繼Apellis報告第三季度Syfovre收入低於預期之後，基本情緒是該公司目前的估值可能無法完全反映市場機會的預期規模。在尋求有關地理萎縮（GA）市場的更多細節時，人們預計C3G/IC-MPGN的潛在引入可能會平衡GA更漸進的進展。
該公司指出，Apellis披露了2024年第三季度的業績，這表明Syfovre的收入有所下降。這歸因於小瓶數量的適度增長，與淨價格下降和競爭加劇形成鮮明對比。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
